EGFR and cancer: This seminal body of work contributed to the development of tyrosine kinase inhibitors (TKIs), prototypes of targeted therapies that have already led to significant advances in the treatment of numerous human cancers, particularly for patients with non-small-cell lung cancer harboring EGFR activating mutations (Nan et al., 2017).